Press Releases

< 2021 >

Filter:

February 11, 2021
Genocea Provides Fourth Quarter 2020 Corporate Update
GEN-011 and GEN-009 clinical trials continue to advance ATLAS TM stimulatory antigen and inhibitory antigen (Inhibigen T...
February 4, 2021
Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compan...
January 28, 2021
Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigens of anti-t...
January 19, 2021
Genocea to Participate in the B. Riley Securities’ Virtual Oncology Investor Conference
CAMBRIDGE, Mass. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
January 4, 2021
Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
CAMBRIDGE, Mass. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical comp...